Protalix BioTherapeutics: Recombinant therapeutic proteins produced using ProCellEx®, plant cell-based protein expression system. Lead asset, PRX-102, modified version of recombinant human alpha-GAL-A protein, in multiple Ph 3 trials for Fabry disease, partnered globally w Chiesi - Interim Ph 3 (PRX-102) data demonstrated improvement in kidney function in pts switched from Replagal® to PRX-102. OPRX-106 is in Ph 2 development for ulcerative colitis and PRX-110 (alidornase alfa) is in Ph 2 development for Cystic Fibrosis.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
ROW
Clinical Stage
Marketed, Phase III
Disease Space
Autoimmune, Gastrointestinal, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Platform Technology
Website:
Address:
2 Snunit Street, Science Park
P.O.B. 455
Carmiel, 20100
Israel

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Clients at Jefferies

New York, NY, United States, June 4 – June 7, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.